Description
SOLORIS (ECULIZUMAB) 300MG/VIAL
First action · last action
2013-09-04 · 2013-09-04
Transactions
1
First transaction's obligation
$37,891
Base + all options value (sum of deltas)
$37,891
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797D30015
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2013-09-04+$37,891= $37,891
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2013-09-04 | +$37,891 | $37,891 | SOLORIS (ECULIZUMAB) 300MG/VIAL |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI DKCXLGANZAN3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36E79726A0021 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36C24526N0739 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $104,650 | FY2026 |
| 36F79726D0143 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36C26026F0055 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $1,255,805 | FY2026 |
| 36C26025F0093 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $626,866 | FY2025 |
| 36C26024F0096 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $522,487 | FY2024 |
Other recipients under 6505 from 598-NORTH LITTLE ROCK (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA25613J0090 | ACTELION PHARMACEUTICALS US, INC. | 598-NORTH LITTLE ROCK | $17,168 | FY2013 |
| VA25612P5262 | MCKESSON PLASMA AND BIOLOGICS LLC | 598-NORTH LITTLE ROCK | $13,529 | FY2012 |
| VA25612P2561 | MCKESSON PLASMA AND BIOLOGICS LLC | 598-NORTH LITTLE ROCK | $13,529 | FY2012 |
| VA25612P2542 | MCKESSON PLASMA AND BIOLOGICS LLC | 598-NORTH LITTLE ROCK | $7,450 | FY2012 |
| VA25612P5266 | MCKESSON PLASMA AND BIOLOGICS LLC | 598-NORTH LITTLE ROCK | $87,825 | FY2012 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA25613F2104_3600_V797D30015_3600 · retrieved 2026-09-26.